Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 | market report: 8 | |||
2 | market report: 2 | |||
3 | market report: 2 | |||
4 |  | market report: 1 | ||
5 | market report: 1 |
Top 5 Key Players companies in PCSK9 Inhibitors
by Most Market Reports in the Japan in 2021
The PCSK9 Inhibitors top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Market Reports PCSK9 Inhibitors Key Players in the Japan. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2021, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
The PCSK9 inhibitors are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels -- by up to 60% in some cases -- when combined with a statin.. PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate an enzyme in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).
Page generation time:
May 17 2025